Sanofi missed expectations for the quarter, with revenue and net income short of analyst expectations. But that didn't send CEO Christopher Viehbacher into second-guessing mode. It certainly didn't inspire a sharp longing for the newly fashionable megadeal.
written on 29.04.2014